

Regd. & Corp. Office:
1506, Chiranjiv Tower,
43, Nehru Place,
New Delhi - 110019 (INDIA)

Tel.: 011 - 47589500-51 (50 Lines),
E-mail: info@medicamen.com
Web: www.medicamen.com
CIN No.: L74899DL1993PLC056594

Ref: STEX/OUTCOME/2019-20

Date: 08.11.2019

BSE Limited
Department of Corporate Services-Listing
PJ Towers, Dalal Street
Mumbai- 400001

Company No.: 531146

Sub. : Outcome of Board Meeting.

Dear Sir,

We wish to inform you that the Board of Directors of the Company at its meeting held today approved the Un-Audited Financial Results of the Company for the quarter and half year ended on September 30, 2019.

Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose the following:

- a) Statement showing the Un-Audited Financial Results of the Company for the quarter and half year ended on September 30, 2019 as **Annexure-A** and
- b) Limited Review Report on the Un- Audited Financial Results as **Annexure-B**

The meeting of the Board of Directors commenced on 12.00 PM and concluded at 02.25 PM.

The Un-Audited Financial Results of the Company for the quarter and half year ended on September 30, 2019, as approved by the Board, will also be available on the Company's website www.medicamen.com.

This is for your information and records.

Thanking You.

Yours faithfully,
For Medicamen Biotech Limited


Rahul Bishnoi
Chairman
DIN: 00317960



KEY HIGHLIGHTS

Medicamen Biotech Limited posts strong Results with a steady revenue growth of 9.31% YoY

- ✓ Revenue Grows for Q1FY20 grows by 9.31% YoY
- ✓ EBITDA for Q1FY20 grows by 1.87% YoY
- ✓ PAT for Q1FY20 grows by 7.79% YoY

Medicamen Biotech Limited) is into manufacturing and marketing of pharmaceutical formulations. The Company has a joint venture and an equity participation with PharmaDanica A/S, Denmark. It is engaged in the manufacturing of wide range of products such as tablets, capsules, liquid syrup and dry syrup (beta lactum and non-betalactum) ointment and Oral Rehydration Solution (ORS). It has marked its strong presence in International Markets having strong hold in ROW market.

The Company's core focus on R&D along with its commitment towards quality has enabled it to offer the best-in-class products, at competitive prices. It has two world-class formulations plants at Bhiwadi (Rajasthan) and Haridwar (Uttarakhand). Both the facilities are equipped with modern-day production systems and are integrated with the cutting-edge technology. Further, it has a perfect blend of technically skilled personnel and hardworking employees.



CAPEX HIGHLIGHTS

- ✓ *Medicamen Biotech limited hereby announcing that Pharma Oncology Formulation Plant at Haridwar shall be operational from December 2019, as per schedule.*
- ✓ *The Company has acquired controlling stake of OPAL Pharmaceuticals Pty Ltd (a company incorporated in Australia) from its existing shareholder which is a marketing and trading company of Pharmaceuticals products.*

OPAL has got 14 market authorizations for Australian Market.

This acquisition shall facilitate MBL to leverage high growth Australian market which has good potential.





MEDICAMEN BIOTECH LIMITED

Annexure -A

Regd. Office: 1506, Chiranjiv Tower, 43, Nehru Place, New Delhi-110019

CIN : L74899DL 1993PLC056594

E-mail : cs@medicamen.com, www.medicamen.com

Un-audited Standalone Financial Results for the quarter and Half Year ended on 30th Sep' 2019

PART I

Rupees in Lacs (Except per Share data)

| Particulars | Quarter Ended | | | Half Year ended | | Year Ended |
|---|------------------------------|--|--|-----------------|-----------------|------------------|
| | 3 Months Ended 30.09.2019 | Preceding 3 Months Ended 30.06.2019 | Corresponding 3 Months Ended 30.09.2018 | 30th Sep' 2019 | 30th Sep' 2018 | 31.03.2019 |
| | Un-audited | Un-audited | Un-audited | Un-audited | Un-audited | Audited |
| 1 Income from operations | | | | | | |
| (a) Net Sales / Income from operations | 3,551.51 | 3,112.91 | 3,248.82 | 6,664.42 | 6,525.16 | 12,260.45 |
| (b) Other Income | 35.30 | 3.84 | 180.54 | 39.14 | 296.83 | 365.87 |
| (c) Total Revenue | 3,586.81 | 3,116.75 | 3,429.36 | 6,703.56 | 6,821.99 | 12,626.32 |
| 2 Expenses | | | | | | |
| a) Cost of Material Consumed | 2,190.67 | 2,154.07 | 2,049.14 | 4,344.74 | 3,983.34 | 7,974.47 |
| b) Purchase of Goods Traded | - | - | - | - | - | 220.73 |
| c) Changes in inventory of Finished Goods and Work in Progress | 73.98 | (69.75) | 106.68 | 4.23 | 369.13 | 139.08 |
| d) Employees Benefits Expenses | 243.85 | 198.16 | 236.99 | 442.01 | 453.78 | 808.55 |
| e) Finance Cost | 21.36 | 16.39 | 35.11 | 37.75 | 70.88 | 93.77 |
| f) Depreciation and Amortisation Expenses | 62.37 | 56.96 | 48.42 | 119.33 | 96.12 | 221.40 |
| g) Other expenses | 472.65 | 329.15 | 442.05 | 801.80 | 883.78 | 1,416.03 |
| Total Expenses | 3,064.88 | 2,684.98 | 2,918.39 | 5,749.86 | 5,857.03 | 10,874.04 |
| 3 Profit/(Loss) before Exceptional Items & Tax (1 - 2) | 521.93 | 431.77 | 510.97 | 953.70 | 964.96 | 1,752.28 |
| 4 Exceptional Items (Commercial Tax Expenses Related to Earlier Years) | - | - | - | - | - | - |
| 5 Profit/(Loss) before Extra Ordinary Items & Tax (3 - 4) | 521.93 | 431.77 | 510.97 | 953.70 | 964.96 | 1,752.28 |
| 6 Tax Expenses | | | | | | |
| Current Year | 150.18 | 111.00 | 159.70 | 261.18 | 293.41 | 549.63 |
| Deferred Tax Liability | (11.97) | (7.36) | (4.71) | (19.33) | (6.63) | 0.07 |
| Total Tax Expense | 138.21 | 103.64 | 154.99 | 241.85 | 286.78 | 549.70 |
| 7 Net Profit /Loss for the period from Continuing operation (5- 6) | 383.72 | 328.13 | 355.98 | 711.85 | 678.18 | 1,202.58 |
| 8 Other Comprehensive Income | | | | | | |
| Item that will not reclassified to Profit & Loss | - | - | - | - | - | - |
| 9 Total Comprehensive Income net of Tax | 383.72 | 328.13 | 355.98 | 711.85 | 678.18 | 1,202.58 |
| 10 Paid up equity share capital (Rs. 10/- per share) | 1,221.66 | 1,221.66 | 1,170.00 | 1,221.66 | 1,170.00 | 1,170.00 |
| 11 Earning Per Share (Rs.) | | | | | | |
| Basic | 3.18 | 2.75 | 3.05 | 5.89 | 5.80 | 10.28 |
| Diluted | 3.18 | 2.75 | 3.05 | 5.89 | 5.80 | 10.28 |

NOTES :

- The above results after being reviewed by the Audit Committee have been taken on record by the Board at its Meeting held on 8th November'2019.
- This statement has been prepared in accordance with the Companies (Indian Accounting Standard) Rules,2015 (Ind AS) prescribed under Section 133 of the Companies Act,2013 and other recognised accounting practices and policies to the extent applicable.
- The company has acquired controlling stake of OPAL Pharmaceuticals Pty Ltd (a company incorporated in Australia) from its existing shareholders on 17th September 2019 which is a marketing and trading company of Pharmaceuticals products.
- Pharma Oncology Plant at Haridwar shall be operational by Dec,2019.
- The company operates only in one business segment , viz. Pharmaceuticals formulations, hence segment reporting is not applicable
- The Earning Per Share has been calculated as per Indian Accounting Standard (Ind AS) 33 -"Earning per Share"
- Limited review Report has been carried out by the Statutory Auditors for the above period.
- The figures are regrouped in previous year also, wherever considered necessary, to make them comparable.

For & on behalf of Board of Directors
Medicamen Biotech Limited



R. Bishnoi
(Rahul Bishnoi)
Chairman

Place : New Delhi

Dated : 8th November'2019



MEDICAMEN BIOTECH LIMITED

Regd. Office: 1506, Chiranjiv Tower, 43, Nehru Place, New Delhi-110019

CIN : L74899DL 1993PLC056594

E-mail : cs@medicamen.com, www.medicamen.com

Rupees in Lacs

| STATEMENT OF ASSETS & LIABILITIES | | | |
|--|---|--|---|
| | Particulars | As at Sep 30, 2019 Un-audited | As at March 31, 2019 Audited |
| A | ASSETS | | |
| 1 | Non-current assets | | |
| | (a) Property, Plant and Equipment | 3,226.85 | 2,404.67 |
| | (b) Intangible assets | 39.08 | 33.43 |
| | (c) Capital work-in-progress | 2,308.00 | 1,475.83 |
| | (d) Financial Assets : Loans and advances | 62.73 | 58.03 |
| | (e) Other Non- current assets | 135.22 | 70.45 |
| | Total Non-current Assets | 5,771.88 | 4,042.41 |
| 2 | Current assets | | |
| | (a) Inventories | 1,281.24 | 1,526.03 |
| | (b) Financial Assets | | |
| | (i) Current investments | - | - |
| | (ii) Trade receivables | 5,725.68 | 4,337.09 |
| | (iii) Cash and Bank Balances | 527.89 | 851.93 |
| | (iv) Loans and advances | 1,047.57 | 1,054.05 |
| | (c) Other current assets | 1,918.42 | 1,847.76 |
| | Total current Assets | 10,500.80 | 9,616.86 |
| | Total Assets | 16,272.68 | 13,659.27 |
| B | EQUITY AND LIABILITIES | | |
| 1 | Equity | | |
| | (a) Equity share capital | 1,221.66 | 1,170.00 |
| | (b) Other Equity | 10,536.89 | 7,493.36 |
| | Total Equity | 11,758.55 | 8,663.36 |
| | LIBILITIES | | |
| 2 | Non-current Liabilities | | |
| | (a) Financial Liabilities : Borrowings | 8.21 | 2.09 |
| | (b) Provisions | 101.12 | 98.02 |
| | (c) Deferred Tax liabilities (Net) | 22.10 | 41.43 |
| | Total Non-current Liabilities | 131.43 | 141.54 |
| 3 | Current Liabilities | | |
| | (a) Financial Liabilities | | |
| | (i) Borrowings | 515.68 | 1,161.33 |
| | (ii) Trade payables | 3,339.38 | 3,056.98 |
| | (b) Other current liabilities | 266.47 | 77.72 |
| | (c) Provisions | 261.18 | 558.34 |
| | | 4,382.71 | 4,854.37 |
| | Total Equity and Liabilities | 16,272.68 | 13,659.27 |

For & on behalf of Board of Directors
Medicamen Biotech Limited



Rahul Bishnoi
(Rahul Bishnoi)
Chairman

Place : Delhi

Dated : 08.11.2019


Independent Auditor's Review Report on Standalone Quarterly Financial Results

To

The Board of Directors,
Medicamen Biotech Ltd.
 1506, Chiranjiv Tower, 43,
 Nehru Place New Delhi-110019

We have reviewed the accompanying statement of unaudited financial results of M/s Medicamen Biotech Limited having its registered office situated at 1506, Chiranjiv Tower, 43, Nehru Place, New Delhi-110019 for the quarter and half year ended September 30, 2019 ("the statement") being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

This statement is the responsibility of the Company's Management and has been approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard ("Ind AS 34") prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Rai Qimat & Associates
 Chartered Accountants

Qimati Garg
 Qimat Rai Garg
 Partner

(Membership Number: 080857)

UDIN - 19080857 A AAAC F6858

Place: Gurugram
 Date: 08.11.2019